-
Daiichi Sankyo and AstraZeneca’s Enhertu gains NMPA approval for HER2 GEJ
23 Jan 2026 12:15 GMT
… drug conjugate discovered by Daiichi Sankyo and jointly developed with … and 97 partial responses.
Daiichi Sankyo China president Michio Hayashi … to show a survival benefit in the second-line … .
In September 2025, Daiichi Sankyo and AstraZeneca received priority …
-
Breast Cancer Therapeutics Market is expected to reach US$ 72.05 Billion by 2033 | DataM Intelligence
21 Jan 2026 14:07 GMT
… uptake. The market is also benefiting from continuous advancements in precision … hormone receptor-positive segments have benefited the most from targeted and … -standard therapies.
Japan:
December 2025: Daiichi Sankyo expanded its Trop2-directed ADC …
-
Cancer R&D is thriving. Here are the areas to watch in 2026.
21 Jan 2026 12:05 GMT
… plagued earlier iterations. Blockbusters like Daiichi Sankyo’s Enhertu, most recently approved … another ADC, raludotatug deruxtecan, with Daiichi Sankyo, which is moving into a … to other disease indications to benefit more patients?” Heffernan said.
Eyes …
-
Enhertu wins Korean approval for HER2-low and HER2-ultra-low metastatic breast cancer
20 Jan 2026 08:41 GMT
Daiichi Sankyo Korea and AstraZeneca … was initially developed by Daiichi Sankyo and was jointly commercialized with … Daiichi Sankyo Korea and AstraZeneca Korea, with distribution handled by Daiichi Sankyo … percent) and the clinical benefit rate was about 1.5 …
-
EMA validates Type II Variation MAA for AstraZeneca, Daiichi’s Enhertu
20 Jan 2026 05:17 GMT
… by Daiichi Sankyo (DSNKY) and being jointly developed and commercialized by Daiichi Sankyo and … , Global Head, R&D, Daiichi Sankyo. “Following the recent approval in … in the EU who may benefit from improved outcomes in a …
-
<![CDATA[T-DXd/Pertuzumab Earns Type II Application Validation in EU for HER2+ mBC]]>
19 Jan 2026 23:30 GMT
… European Union] who may benefit from improved outcomes in … Subgroup analyses demonstrated a benefit regardless of de novo … data showed meaningful PFS benefit across the previously outlined … breast cancer. News release. Daiichi-Sankyo. January 19, 2026. Accessed …
-
<![CDATA[EMA Validates T-DXd for First-Line HER2+ Metastatic Breast Cancer]]>
19 Jan 2026 23:33 GMT
… , global head, Research and Development, Daiichi Sankyo, in a news release.1 … in the EU who may benefit from improved outcomes in a … metastatic breast cancer. News release. Daiichi Sankyo. January 19, 2026. Accessed January …
-
Tenosynovial Giant Cell Tumors Market to Show Significant Growth by 2034 as CSF1R-Targeted Therapies Drive the Next Wave | DelveInsight
19 Jan 2026 18:00 GMT
… for surgery or unlikely to benefit from it. Top-line results … Therapeutics, Abbisko Therapeutics, AmMax Bio, Daiichi Sankyo, Deciphera Pharmaceuticals (now a wholly … Competition
10.2
TURALIO (pexidartinib): Daiichi Sankyo
10.2.1
Product Description …
-
EU starts review of first-line Enhertu for breast cancer
19 Jan 2026 17:09 GMT
… has started its review of Daiichi Sankyo and AstraZeneca's Enhertu … data has not revealed any benefit over the comparator arm.
Daiichi …
-
Global oncology experts gathered in Korea to discuss ADC-based cancer treatment strategies
19 Jan 2026 11:09 GMT
… , and gastric cancer.
On Saturday, Daiichi Sankyo Korea hosted the “DSKR Oncology … with domestic and international experts,” Daiichi Sankyo Korea President Kim Jeong-tae … academic exchanges to provide treatment benefits to more patients based on …
About
© 1995-2026